Immix Biopharma receives strategic investment from Goose Capital

LOS ANGELES - Immix Biopharma, Inc. (NASDAQ:IMMX), a clinical-stage biopharmaceutical company with a market capitalization of $62 million and impressive six-month stock gains of 41%, has secured a strategic investment from Goose Capital and its founding member Dr. Nancy T. Chang, the company announced Monday.

Dr. Chang, former CEO of Tanox, Inc., brings significant pharmaceutical development experience to the relationship. At Tanox, she led the development of several FDA-approved medications including XOLAIR for severe asthma, TROGARZO for HIV, and EBGLYSS for dermatitis, which have collectively generated over $5 billion in sales. Tanox was later acquired by Genentech/Roche. According to InvestingPro data, Immix maintains a strong balance sheet with more cash than debt, though the company is rapidly utilizing its cash reserves for development activities.

Immix Biopharma is currently developing NXC-201, a BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy for AL Amyloidosis. The treatment is being evaluated in the U.S. multi-center NEXICART-2 study, which has a registrational design. The company reported that the trial’s primary endpoint was met at interim results presented at ASCO 2025.

"We are thrilled that Dr. Chang and Goose recognize the opportunity for commercialization of NXC-201 in relapsed/refractory AL Amyloidosis, other serious diseases, and beyond," said Ilya Rachman, CEO of Immix Biopharma, in the press release statement.

NXC-201 has received Regenerative Medicine Advanced Therapy designation from the FDA and Orphan Drug Designation from both the FDA and the European Medicines Agency.

The financial terms of the investment were not disclosed in the announcement.

Goose Capital is an investment firm comprised of former Fortune 500 executives, industry leaders, and entrepreneurs that focuses on breakthrough technologies and early-stage startups. Analysts following the company have set an ambitious $7 price target, suggesting significant upside potential. Get deeper insights into Immix’s financial health and growth prospects with InvestingPro, which offers exclusive financial metrics and analysis tools for informed investment decisions.

In other recent news, Immix Biopharma, Inc. has reported significant developments regarding its NXC-201 CAR-T cell therapy. The company announced that it plans to seek external partnerships for its NXC-201 programs targeting diseases beyond relapsed/refractory AL Amyloidosis, while continuing to dose patients in these additional areas. Immix Biopharma also highlighted the favorable safety profile of NXC-201, noting the absence of neurotoxicity in low-volume disease patients, as it advances its NEXICART-2 clinical trial. This trial, which aims to secure FDA approval for NXC-201 as the first cell therapy for AL amyloidosis, has been expanded to 18 sites across the United States to improve patient access. The expansion comes amidst accelerated progress in the trial, which was recently acknowledged by H.C. Wainwright, as the firm reiterated its Buy rating and set a $7.00 price target for the stock. These developments reflect Immix Biopharma’s strategic efforts to advance its clinical programs and seek regulatory approval for its innovative therapies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.